{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:37:01Z","timestamp":1762364221785,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2024.09.030","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T16:41:42Z","timestamp":1730220102000},"page":"330.e1-330.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bempegaldesleukin plus nivolumab in first-line advanced\/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)"],"prefix":"10.1016","volume":"43","author":[{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Balar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikala S","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Penkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandr","family":"Vasiliev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avivit","family":"Peer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Harputluo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shermeen","family":"Poushnejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anila","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A.","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Zalevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.09.030_bib0001","unstructured":"National Comprehensive Cancer Network: NCCN clinical practice guidelines in Oncology Bladder Cancer (Version 1. 2024) [Internet] Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417, Access 6 Feb 2024."},{"key":"10.1016\/j.urolonc.2024.09.030_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0003","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0005","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0006","unstructured":"Proleukin\u00ae (aldesleukin). Prescribing information [Internet], 2012 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103293s5130lbl.pdf. Access 6 Feb 2024."},{"key":"10.1016\/j.urolonc.2024.09.030_bib0007","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214: an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A first-in-human study and biomarker analysis of NKTR-214, a novel IL2r\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.2545","article-title":"Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy","volume":"35","author":"Bernatchez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0012","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0013","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.21.00675","article-title":"Bempegaldesleukin plus nivolumab in first-line metastatic melanoma","volume":"39","author":"Diab","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0014","unstructured":"Siefker-Radtke AO, Cho DC, Diab A, et al. Bempegaldesleukin plus nivolumab in first-line metastatic urothelial carcinoma: results from PIVOT-02 [Internet]. Eur Urol 0, 2022 [cited 2022 Jun 9] Available from: https:\/\/www.europeanurology.com\/article\/S0302-2838(22)02335-1\/fulltext. Access 6 Feb 2024."},{"key":"10.1016\/j.urolonc.2024.09.030_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004419","article-title":"Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study","volume":"10","author":"Tannir","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/fon-2020-0795","article-title":"PIVOT-10: phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer","volume":"17","author":"Huddart","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0017","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0018","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.23.02082","article-title":"Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: a phase III randomized study (PIVOT-09)","volume":"42","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0020","unstructured":"Matsubara N, Wit R de, Balar AV, et al. Pembrolizumab with or without lenvatinib as first-line therapy for patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind trial [Internet]. Eur Urol 0, 2023[cited 2023 Dec 13] Available from: https:\/\/www.europeanurology.com\/article\/S0302-2838(23)03064-6\/fulltext. Access, 6 Feb 2024."},{"key":"10.1016\/j.urolonc.2024.09.030_bib0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0023","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0024","unstructured":"Bristol Myers Squibb provides update on checkmate -901 trial evaluating opdivo (nivolumab) plus yervoy (ipilimumab) as first-line treatment for patients with unresectable or metastatic urothelial carcinoma [Internet][cited 2023 Jan 5]. Available from:https:\/\/news.bms.com\/news\/corporate-financial\/2022\/Bristol-Myers-Squibb-Provides-Update-on-CheckMate\u2013901-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma. Access, 6 Feb 2024."},{"key":"10.1016\/j.urolonc.2024.09.030_bib0025","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0026","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2024.09.030_bib0027","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:41Z","timestamp":1762363961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1078143924006719"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.030","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bempegaldesleukin plus nivolumab in first-line advanced\/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}